News & Events
Lanterne Dx Presenting 6-plex & ISH/IF Posters at AACR 2023
The Lanterne Dx Team will be attending the American Association for Cancer Research 2023 Annual meeting April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida. Meet our team over in booth 1808 to learn about how Lanterne Dx can help with your biomarker and image analysis needs. Also come check out our posters:
- (Abstract Number 2322) on Monday, April 17th from 9AM-12:30PM. We will be presenting “Precision immuno-oncology (IO) ISH/IF multiplex panel: Spatial detection of cytokines and IO biomarkers”
- (Abstract Number 6666) on Wednesday, April 19th from 9AM-12:30PM. We will be presenting “Multispectral imaging to detect immune phenotypes in pre and post therapy breast cancer patient specimens”.
Lanterne Dx is a full-service clinical histopathology CRO offering clinical and translational research and biomarker services combined with robust image analysis and data analysis to accelerate drug development. Applying innovative technical expertise and a flexible, customer-centric approach, Lanterne Dx improves patient care by partnering with translational science leaders to reach critical drug development milestones through well-designed clinical programs and customizable biomarker analysis.
Lanterne Dx to Present Multiplexing TME Data at SITC 2022
Data generated in partnership with Akoya Biosciences will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 8-12 at the Boston Convention and Exhibition Center in Boston, MA and virtually. Stop by Booth 535 to discuss how we can help!
On Thursday, November 10th and Friday November 11th, Lanterne Dx will present scientific posters titled, Multispectral Imaging to Detect Immune Phenotypes Within the Tumor Microenvironment in a Multi-Tissue Study and Whole-slide Multispectral Imaging Reveals the Immune Subtypes of Melanoma Associated with the Tumor Microenvironment. As immune profiling is becoming an important tool in immunotherapy, biomarkers that detect the tumor and tumor microenvironment allow for the development of strategies that accelerate the development of treatments that enhance a patient’s immune system. As a collaborative effort with Akoya Biosciences, Lanterne Dx will demonstrate the use of the MOTiF™ PD-1/PD-L1 Panel kit in multiple tissue types.
Applying innovative technical expertise and a flexible, customer-centric approach, Lanterne Dx improves patient care by partnering with translational science leaders to reach critical drug development milestones through well-designed clinical programs and customizable biomarker analysis.
Lanterne Dx is a full-service clinical histopathology CRO offering clinical and translational research and biomarker services combined with robust image analysis and data analysis to accelerate drug development.
Lanterne Dx Announces CAP Accreditation
Boulder, CO (May 25, 2022) – Lanterne Dx, LLC announced today that that they received their official CAP (College of American Pathologist) accreditation. A CAP laboratory is an internationally recognized program and a leader in the industry. According to CAP, they accredit ” the entire spectrum of laboratory test disciplines using the most scientifically rigorous customized checklist requirement.” These checklists have been developed from meticulous accreditation standards that are more rigorous than or equal to the requirements of Clinical Laboratory Improvement Program (CLIA).
As a CAP accredited laboratory, Lanterne Dx is required to have numerous policies and procedures in place to ensure quality laboratory testing and patient safety. “Accreditation by CAP is a symbol of quality that increases the value of our laboratory to partners, patients and customers.” said Navi Mehra, Lanterne Dx’s Director of Operations.
For more information, please contact info@lanternedx.com.
Lanterne Dx to Present Innovative Multiplex Data at SITC 2021
Boulder, CO (November 9, 2021) – Lanterne Dx, LLC, announced today that new data generated in partnership with Akoya Biosciences will be presented at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 10-14 at the Walter E. Washington Convention Center in Washington, DC and virtually.
On Friday, November 12th, Lanterne Dx will present a scientific poster titled, Advanced Understanding of the Tumor Microenvironment with Multiplex Immunofluorescence. As immune profiling is becoming an important tool in immunotherapy, biomarkers that detect the tumor and tumor microenvironment allow for the development of strategies that accelerate the development of treatments that enhance a patient’s immune system. As a collaborative effort with Akoya Biosciences, Lanterne Dx will demonstrate the use of the MOTiF™ PD-1/PD-L1 Panel kit in multiple tissue types.
“Partnering with Akoya Biosciences is key for our continued growth and innovation at Lanterne Dx. Providing our clients with the most enhanced multiplexing technology to offer improved tumor microenvironment understanding and the highest quality data is at the forefront of this partnership.” said Navi Mehra, Lanterne Dx’s Director of Operations.
Applying innovative technical expertise and a flexible, customer-centric approach, Lanterne Dx improves patient care by partnering with translational science leaders to reach critical drug development milestones through well-designed clinical programs and customizable biomarker analysis.
For more information about Lanterne Dx and activities at SITC 2021, please visit lanternedx.com.
Lanterne Dx to Exhibit and Present Poster at SITC 2021
HTL Clinical Announces Name Change to Lanterne Dx
Boulder, CO (September 1, 2021)
HTL Clinical announced today that it has changed its name to Lanterne Dx. “In order to expand our clinical brand that better resonates with our customers and represents who we are in the marketplace, we determined that our name needed to reflect our growth.” Jon Bishop CEO.
The new Lanterne Dx brand, illustrates the desire to guide research around knowledge and truth. The brand reflects the believe that by gathering reliable, factual information and collaborating with customers, Lanterne Dx can improve data and research for their clients.
Applying innovative technical expertise and a flexible, customer-centric approach, Lanterne Dx improves patient care by partnering with translational science leaders to reach critical drug development milestones through well-designed clinical programs and customizable biomarker analysis.
Founded in 2019 as HTL Clinical, Lanterne Dx is a full-service histopathology contract research organization (CRO) offering medically relevant non-clinical and clinical services to the pharmaceutical, biotech, and academic communities.
Lanterne Dx resides in a newly renovated CLIA-certified and CAP compliant facility in Boulder, Colorado. Visit lanternedx.com for more information.
Lanterne Dx remains committed to growing our capabilities to support routine and specialized histopathology, IHC/ISH, and digital pathology
services. Our team of experts is comprised of board-certified DVM and MD pathologists, trained histotechnicians, PhD scientists, project managers, and hands-on upper management. With our primary focus in oncology and translational science, we provide substantiated expertise in clinical trial services and laboratory diagnostics to enable confident, data-driven decisions.
There is an ongoing commitment to operate in a highly efficient manner to save YOU time and expense. Our team understands the importance of your programs and is focused on doing what it takes to deliver exceptional quality on a timely basis.
It’s Happening!
Did you know what industry sector finished second to Silicon Valley for Venture Capital startup funding in 2018? Pharmaceutical and biotech startups!! Venture capitalists invested
Contact
Reach out to get the latest in pricing and services.